Antibodies

22 Apr 2021 Toripalimab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer Reached Primary Endpoints in Phase III Clinical Study
22 Apr 2021 The NDA of the Novel Anti-PD-1 mAb Serplulimab of Henlius Accepted by NMPA and Proposed to be Granted Priority Review
22 Apr 2021 SAB Biotherapeutics Doses First Patient with SAB-185 for the Treatment of COVID-19 in NIH’s ACTIV-2 Phase 2/3 Clinical Trial
21 Apr 2021 Transcenta Received IND Clearance from US FDA for Initiating Phase I Clinical Trial for its Bi-functional Anti-PD-L1/TGF-β Antibody TST005
20 Apr 2021 Amgen's Investigational Targeted Treatment Bemarituzumab Granted Breakthrough Therapy Designation
20 Apr 2021 Incyte and MorphoSys Announce First Patient Dosed in Phase 3 inMIND Study Evaluating the Addition of Tafasitamab to Lenalidomide and Rituximab in Relapsed or Refractory Follicular or Marginal Zone Lymphoma
19 Apr 2021 European Commission approves second indication of Sarclisa® (isatuximab) for relapsed multiple myeloma
19 Apr 2021 Agenus Submits Balstilimab Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical Cancer
19 Apr 2021 Transcenta Announced Successful First Patient Dosed in Phase I Clinical Study of TST001 Combined with CAPOX for the Treatment of Patients with First-line Locally Advanced Unresectable or Metastatic Gastric Cancer
19 Apr 2021 Humanigen Reports Positive Data With Lenzilumab in the ZUMA-19 CAR-T Phase 1b Study in DLBCL and Plans to Initiate a Potential Registrational Study
18 Apr 2021 U.S. Food and Drug Administration Approves Opdivo® (nivolumab) in Combination with Chemotherapy for Patients with Advanced or Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma, Regardless of PD-L1 Expression Status
16 Apr 2021 GSK and Vir Biotechnology Announce EMA Review of Dual-Action Monoclonal Antibody VIR-7831 for the Early Treatment of COVID-19
16 Apr 2021 Janssen Showcases Phase 2 Nipocalimab (M281) Data in Adults with Generalized Myasthenia Gravis (gMG) at the 2021 American Academy of Neurology Virtual Meeting
16 Apr 2021 Qilu Pharmaceutical and Peptron Sign License Agreement for anti-MUC1 ADC
16 Apr 2021 Lilly requests revocation of emergency use authorization for bamlanivimab alone to complete transition to bamlanivimab and etesevimab together for treatment of COVID-19 in the U.S.
15 Apr 2021 Merck to Discontinue Development of MK-7110 for COVID-19
15 Apr 2021 Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) in Combination with Cabometyx (cabozantinib) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma
15 Apr 2021 GSK provides update on feladilimab, an investigational inducible T cell co-stimulatory (ICOS) agonist
14 Apr 2021 U.S. FDA Grants Accelerated Approval to Trodelvy® for the Treatment of Metastatic Urothelial Cancer
13 Apr 2021 Adagio Therapeutics Initiates Global Clinical Trial of ADG20 as a Treatment for COVID-19
13 Apr 2021 Celldex Presents Promising Data from ILT4/PD-(L)1 Bispecific Antibody Program at AACR 2021
13 Apr 2021 Immunocore presents phase 3 data comparing tebentafusp with investigator’s choice in the clinical trial plenary session at the American Association for Cancer Research 2021 Annual Meeting
13 Apr 2021 Harbour BioMed Presents Novel Antibody for Cancer Immunotherapy at 2021 American Association for Cancer Research Annual Meeting
12 Apr 2021 Heat Biologics Announces New Preclinical Data on PTX-35, Demonstrating Decreased Regulatory T-cell (Treg) Activity and Delayed Tumor Progression at American Association for Cancer Research (AACR) Annual Meeting 2021
12 Apr 2021 Shattuck Labs Highlights Preclinical Data for SL-9258 (TIGIT-Fc-LIGHT) in an Acquired Resistance Model and Expanded Preclinical Data from the GADLEN™ Platform at AACR 2021

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2020 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top